Endomag

Endomag

We're creating the next generation of instruments to help surgeons and radiologists tackle breast cancer. #Sentimag #Magseed #Sienna. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€282m (Public information from Apr 2024)
Company register number 06227698
Cambridge England (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
GBP2010202020212022
Revenues-9.8m15.3m18.3m
% growth--57 %19 %
EBITDA(<1m)(2.2m)(3.6m)(4.0m)
% EBITDA margin-(22 %)(24 %)(22 %)
Profit(<1m)(1.6m)(3.1m)(4.1m)
% profit margin-(16 %)(20 %)(22 %)
  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Spinout

£1.2m

Series A

£600k

Series A

£2.1m

Series B

£2.0m

Series B

£8.0m

Series C

£15.0m

Series D
*

$310m

Valuation: $310m

Acquisition
Total Funding€34.7m

Recent News about Endomag

Edit
More about Endomaginfo icon
Edit

Endomag is a pioneering company in the medical technology sector, specializing in advanced solutions for breast cancer care. The company serves healthcare providers, particularly breast cancer surgeons and radiologists, by offering a unique platform that combines lesion localization and sentinel node biopsy. This platform eliminates the need for wires and radioactive materials, thereby enhancing the precision and flexibility of breast cancer surgeries. Operating in the global healthcare market, Endomag's business model revolves around the sale and distribution of its proprietary medical devices and technologies. Revenue is generated through direct sales to hospitals and clinics, as well as through partnerships with medical institutions. Endomag's innovative approach aims to improve surgical outcomes and patient experiences, making it a key player in the fight against breast cancer.

Keywords: breast cancer, lesion localization, sentinel node biopsy, medical technology, healthcare, surgery, precision, flexibility, non-radioactive, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.